My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

40.50 -5.75 (-12.44%)
Streaming Delayed Price Updated: 2:53 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about LENZ Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada
Exclusive agreement includes over $70 million in upfront and milestone payments to LENZ in addition to double-digit royalties on net sales 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Present at Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net sales 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Host Commercial Day on April 15, 2025
Event to highlight the commercialization strategy and progress towards the potential approval of LNZ100 for the treatment of presbyopia 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports Third Quarter 2024 Financial Results
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
FDA sets Prescription Drug User Fee Act (PDUFA) target date of August 8, 2025 
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Participate in Upcoming Investor Conferences
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports Second Quarter 2024 Financial Results
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference
From LENZ Therapeutics, Inc.
Via GlobeNewswire
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From LENZ Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.